Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients

American Surgeon

Volumn 65, Issue 6, 1999, Pages 500-506

  Pendas, Solange ^a   Dauway, Emilia ^a   Cox, Charles E ^a   Giuliano, Rosemary ^a   Ku, Ni Ni ^a   Schreiber, Robert H ^a   Reintgen, Douglas S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; DYE; TECHNETIUM SULFUR COLLOID TC 99M;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; VITAL STAIN;

AXILLA; BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES;

EID: 0033043382     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Dowlatshahi K, Fan M, Snider HC. Lymph node micrometastases from breast carcinoma: Reviewing the dilemma. Cancer 1997;80:1188-97.
2. Shoenfeld A, Lugamani Y, Smith D, et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 1994;54:2986-90.
3. Noguchi S, Aihara T, Motomura K, et al. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Am J Pathol 1996;2:649-56.
4. Noguchi S, Aihara T, Motomura K, et al. Histologic characteristics of breast cancers with occult lymph node metastases detected by keratin 19 mRNA reverse transcriptase-polymerase chain reaction. Cancer 1996;78:1235-40.
5. Albertini JJ, Lyman GH, Cox CE, Reintgen DS, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
6. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-8.
7. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-9.
8. Turner RR, Ollila DW, Krasne DL, Guiliano AE. Histopathological validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-6.
9. Giuliano AE. Lymphatic mapping and sentinel node biopsy in breast cancer (Letter). JAMA 1997;277:791-2.
10. Giuliano AE, Jones RC, Brennan M, Statman RR. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
11. Ku NK, Ahmad N, Smith PV, Cox CE, Reintgen DS, Nicosia SV. Intraoperative imprint cytology of sentinel lymph nodes in breast cancer. Acta Cytol 1997;41:1606-7.
12. Frazier TG, Wong WYR, Rose D. Implications of accurate pathologic margins in the treatment of primary breast cancer. Arch Surg 1989;124:37-8.
13. Renton SC, Gazet JC, Ford HT, et al. The importance of the resection margin in conservative surgery for breast cancer. Eur J Surg Oncol 1996;22:17-22.
14. Shabaik AS, Cox CE, Clark RA, Reintgen DS. Imprint cytology of needle-localized breast lesions. Acta Cytol 1992; 11-14.
15. Smitt MC, Nowels KW, Zbedlick JS, et al. The importance of the lumpectomy surgical margin status in long term results of breast conservation. Cancer 1995;78:259-67.
16. Tribe C. A comparison of rapid methods including imprint diagnosis for the diagnosis of breast tumors. J Clin Pathol 1973; 26:273-7.
17. Anderson BO, Austin-Seymour M, Gralow J, et al. A multidisciplinary approach to locoregional management of the axilla for primary operable breast cancer. Cancer Control 1997 (In press).
18. 1 carcinoma of the breast? J Am Coll Surg 1997;184:397-8.
19. Ruffin WK, Stacey-Clear A, Younger J, Hoover HC. Rationale for routine axillary dissection in carcinoma of the breast. J Am Coll Surg 1995;180:245-51.
20. Graversen HP, Blichert-Toft M, Andersen JA, Zedeler K. Breast cancer: Risk of axillary recurrence in node negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988; 14:407-12.
21. Cady B. Is axillary lymph node dissection necessary in routine management of breast cancer? No. Important Adv Oncol 1996;251-265.
22. Haffty BG, Ward B, Pathare P. Reappraisal of the role of axillary lymph node dissection in conservative treatment of breast cancer. J Clin Oncol 1997;15:691-700.
23. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 1997;349:1864-7.
24. Noguchi M. Node negative breast cancer patients exposed to unnecessary perioperative risk and increased long-term morbidity (Letter). Ann Surg 1997;225:126-36.
25. International (Ludwig) Breast Cancer Study Group. Clinical practice: Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
26. Wells CA, Heryet A. The immunocytochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984;50: 193-7.
27. Hainsworth PJ, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993;80: 459-63.
28. Schreiber RH, Solange P. Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. Ann Surg Oncol 1998 (In press).